Skip to main content

SMARCA4-deficient Malignant Tumors clinical trials at UCSF

1 research study open to eligible people

SMARCA4-deficient malignant tumors are a type of cancer. UCSF is recruiting for a clinical trial called "Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers." This trial is studying two immunotherapy drugs as a possible treatment for INI1-negative cancers. Participants will receive both drugs together.

Showing trials for

Our lead scientists for SMARCA4-deficient Malignant Tumors research studies include .

Last updated: